Guardant Health (FRA:5GH) Research & Development: €315.1 Mil (TTM As of Mar. 2026)


FRA:5GH Guardant Health Inc FRA:5GH
67 GF Score
Price €124.64
GF Value €50.44
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Guardant Health Research & Development?

Guardant Health FRA:5GH +2.03% 67 Research & Development is €315.1 Mil as of Mar. 2026. GuruFocus rates FRA:5GH with a GF Score™ of 67/100 and a GF Value™ of €50.44 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Guardant Health's Research & Development for the three months ended in Mar. 2026 was €78.7 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €315.1 Mil.

Guardant Health  (FRA:5GH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Guardant Health Research & Development Related Terms

Guardant Health Research & Development Historical Data

* Premium members only.

The historical data trend for Guardant Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guardant Health Research & Development Chart

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 232.95 352.87 336.72 332.10 311.02

Guardant Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.88 75.82 76.64 83.92 78.75
FRA:5GH
67GF Score
Guardant Health Inc FRA:5GH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guardant Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €315.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €315.1 Mil mean?
Guardant Health (FRA:5GH) has a Research & Development of €315.1 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Guardant Health and its competitors.
Is Guardant Health's Research & Development too high?
Guardant Health's current Research & Development is €315.1 Mil. Overall, Guardant Health has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Guardant Health's Research & Development compare to LH and DGX?
Guardant Health's Research & Development of €315.1 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Guardant Health and its competitors. Guardant Health's current Research & Development is €315.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guardant Health stock overvalued right now?
Based on GuruFocus' analysis, Guardant Health (FRA:5GH) is currently considered Significantly Overvalued. The stock's GF Value™ is €50.44, compared to a current price of €124.64 — trading 147.1% above its estimated fair value. The current Research & Development is €315.1 Mil. Guardant Health's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Guardant Health (FRA:5GH), the current Research & Development is €315.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guardant Health (FRA:5GH) Overvalued in 2026?

Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued. The current stock price of €124.64 is trading 147.1% above its estimated GF Value™ of €50.44. GuruFocus considers Guardant Health to be Significantly Overvalued.

Key valuation signals for FRA:5GH:

  • Research & Development: €315.1 Mil
  • GF Value™: €50.44 vs. price of €124.64 (147.1% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the FRA:5GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guardant Health Business Description

Other Exchanges GH:USA1GH:Italy5GH:Germany
Address 3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
67GF Score

Get the complete analysis for FRA:5GH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€124.64
Price
€50.44
GF Value